

September 7, 2006
AnGes MG, Inc.

AnGes MG Submitted the Notification of the Clinical Trial Plan
for NF-κB Decoy Oligo
- Phase II Clinical Trials of NF-κB Decoy Oligo
for the Treatment of Atopic Dermatitis Commences -

AnGes MG's notification of the clinical study plan for Phase II clinical trials of NF-κB decoy oligo for the treatment of atopic dermatitis was submitted to the Pharmaceuticals and Medical Devices Agency. AnGes MG, Inc. is pleased to announce that contracts were concluded with medical institutions in charge of conducting the trials, and the Phase II trials will be commenced shortly.

NF-κB decoy oligo is being developed as a nucleic acid drug indicated for immuno-inflammatory diseases such as atopic dermatitis and rheumatoid arthritis. Of these, atopic dermatitis is a disease for which the development of a new treatment drug is eagerly awaited, since, although there are believed to be as many as 1.4 million patients in Japan, effective treatment methods have yet to be developed.

NF-κB decoy oligo, because of its characteristic of specifically suppressing transcription factors, has the potential to become an epoch-making atopic dermatitis drug that is effective and induces few adverse reactions and therefore AnGes MG has been stepping up the clinical development of this drug in Japan.

The Phase II clinical trials will be carried out in patients with atopic dermatitis of moderate or severer lesions on the face to investigate the efficacy and safety of application of NF-κB decoy oligo ointment and to find its optimal dose.

Development in Japan of NF-κB decoy oligo used in the treatment of atopic dermatitis is being carried out in alliance with Alfresa Pharma Corporation.

<Reference>

Development Status of NF-κB Decoy Oligo

Field of indications	Region	Development Phase	Licensee
Atopic dermatitis	Japan	Phase II clinical trial under preparation	Alfresa Pharma Corporation
Psoriasis		Preclinical	Undecided
Rheumatoid arthritis		Clinical trial under preparation	Undecided
Osteoarthritis		Preclinical	Undecided
Prevention of vascular restenosis		Clinical trial under preparation	Goodman Co., Ltd.